During the past decade, Klinische Forschung Berlin-Mitte GmbH conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 19 clinical trials were completed, i.e. on average, 111.8% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 8 clinical trials were completed. i.e. 133.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Klinische Forschung Berlin-Mitte GmbH" #1 sponsor was "Pfizer" with 8 trials, followed by "Hoffmann-La Roche" with 3 trials sponsored, "Shire" with 3 trials sponsored, "Idorsia Pharmaceuticals Ltd." with 2 trials sponsored and "Janssen Vaccines & Prevention B.V." with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Klinische Forschung Berlin-Mitte GmbH" #1 collaborator was "Breast International Group" with 2 trials as a collaborator, "OCT Clinical Trials" with 2 trials as a collaborator, "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator, "Analyze & Realize" with 1 trials as a collaborator and "Austrian Breast and Colorectal Cancer Group" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Klinische Forschung Berlin-Mitte GmbH" are "Binge Eating Disorder" (3 trials), "Breast Cancer" (2 trials), "Insomnia Disorder" (2 trials), "Rheumatoid Arthritis" (2 trials) and "Smoking Cessation" (2 trials). Many other conditions were trialed in "Klinische Forschung Berlin-Mitte GmbH" in a lesser frequency.

Most popular intervention types in "Klinische Forschung Berlin-Mitte GmbH" are "Drug" (23 trials), "Other" (5 trials), "Biological" (4 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Atezolizumab" (2 trials), "Lisdexamfetamine dimesylate" (2 trials), "Nicotine Replacement Therapy Patch" (2 trials) and "bupropion hydrochloride" (2 trials). Other intervention names were less common.

The vast majority of trials in "Klinische Forschung Berlin-Mitte GmbH" are 27 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Klinische Forschung Berlin-Mitte GmbH". undefined are not yet recruiting, 1 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 20 completed trials in Klinische Forschung Berlin-Mitte GmbH, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Klinische Forschung Berlin-Mitte GmbH, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 1 trials that are defined as “Not Applicable".